NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design Announces Proposed Public Offering of Common Stock
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell up to 16,000,000 shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by
View HTML
Toggle Summary Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Design's investigational
View HTML
Toggle Summary Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
CMB305 Monotherapy vs. Placebo in the Maintenance Setting PFS Analysis for Potential Full Approval as Early as 24 Months After Study Start Conference Call and Webcast Tomorrow at 5:30am PT/8:30am ET SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Immune Design
View HTML
Toggle Summary Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 32 nd Annual
View HTML
Toggle Summary New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that an interim analysis of its ongoing, randomized
View HTML
Toggle Summary Immune Design to Present at Upcoming Investor Conferences in September
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that the company will present at two upcoming investor conferences in September.
View HTML
Toggle Summary Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress
Interim data analysis shows greater clinical benefit and immune response with CMB305+atezolizumab than with atezolizumab alone SEATTLE and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today
View HTML
Toggle Summary Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Company conference call at 1:30 p.m. PT today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2017 Financial Results & Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report second quarter 2017 financial results and provide a corporate update after the close of U.S.
View HTML
Toggle Summary Immune Design Updates Positive Data from Lead Cancer Immunotherapy Programs at ASCO Annual Meeting
Observed median overall survival for sarcoma patients treated in two separate Phase 1 studies with an NY-ESO-1 targeted novel immunotherapy meaningfully exceeds standard of care benchmarks In follicular NHL patients, intratumoral immunization with G100 induced objective responses ( ≥ 50%
View HTML